FDA Implements Sweeping Policy Changes to Accelerate Drug Approvals and Transform Regulatory Landscape

The U.S. Food and Drug Administration launched new policies in 2025 that could dramatically impact drug approvals and enforcement activity in the coming year. From broadening its advertising enforcement to accelerating development programs and publishing Complete Response Letters (CRLs), FDA has created new uncertainties for the life sciences industry.

Radical Transparency Through Public CRLs

In a move that FDA called "radical transparency," the agency changed its historic policy of keeping CRLs to drug and biologic applicants confidential. Kurt Karst, a director at Hyman, Phelps & McNamara (搜索)搜索该词条, said making CRLs public takes away companies' ability to control their narrative and gives competitors insights into FDA concerns. Companies could put together pieces from several CRLs in a particular therapeutic area to "leapfrog over a potential competitor," he said.

On the positive side, Karst noted that companies gain insight into FDA decision-making and the most common deficiencies identified in CRLs. In addition, he said "FDA has cracked the door open" to seek additional information in FDA reviews, such as generic drug exclusivity decisions for abbreviated new drug applications.

Controversial Fast-Track Review Program

FDA has taken numerous steps to speed up product reviews. Its most notable and controversial action was the launch of the Commissioner's National Priority Review Voucher pilot program. Companies selected for the program receive a voucher entitling them to an approval decision within one to two months. To qualify, their products must support U.S. national interests.

Melissa Mannion, of counsel at Jones Day (搜索)搜索该词条, said there is skepticism as to whether product reviews can be completed in 30 to 60 days. Karst questioned where reviewers would come from given staff cuts, what other areas would suffer because of the reallocation of work, and if reviews would be rushed.

Members of Congress have criticized the program for being launched without congressional authorization or rulemaking. In a letter to FDA Commissioner Martin Makary, Rep. Frank Pallone, Jr., D-NJ, House Energy and Commerce Committee Ranking Member, and Sen. Bernie Sanders, I-VT, Senate Health, Education, Labor, and Pensions Committee Ranking Member, said the program's "absurdly short timelines" are inconsistent with those in user fee agreements. They said the program could undermine public confidence in FDA's decisions, raise safety concerns and benefit those politically favored by President Trump.

Ultra Rare Disease Pathway

The agency is also seeking to speed approval of drugs for ultra rare diseases (搜索)搜索该疾病. In November, Vinay Prasad, director of the Center for Biologics Evaluation and Research, and Commissioner Makary published a paper announcing a new "plausible mechanism pathway" to accelerate drug approval for ultra rare diseases, based on mechanism of action and limited clinical data.

Mannion noted that under this pathway the agency would accept a much smaller amount of pre-market data than it does for other accelerated pathways and will likely have very robust post-marketing requirements.

Biosimilar Development Acceleration

The agency also aims to speed up development of biosimilars (搜索)搜索该药品 by eliminating the need for comparative efficacy studies for many biosimilars. FDA issued draft guidance in October stating that a human pharmacokinetic similarity study and an assessment of immunogenicity may be sufficient to evaluate whether there are clinically meaningful differences between the proposed biosimilar and the reference product in terms of safety, purity and potency.

Mannion noted that removing clinical data from the approval requirements would have implications for the patent litigation process as well as biosimilar development. A faster biosimilar timeline raises "questions around potential earlier initiation of the patent dance and IP considerations," she said.

Enhanced Advertising Enforcement

Mannion noted that the agency's advertising enforcement letters are focusing on different aspects of pharmaceutical promotional activity. FDA has shifted its attention to compounding pharmacies and telehealth platforms. For example, it has objected to ads for compounded GLP-1 (搜索)搜索该药品 products that imply they are the same as FDA-approved products by saying they have the same active ingredient or proven effectiveness.

FDA has expanded what it views as problematic. FDA is now using its AI tool Elsa to identify ads it believes are even slightly misleading. Thousands of general warning letters have been sent without citing specific regulatory violations. Most of the letters point to general reasons why an advertisement might be misleading rather than a specific provision of the Food, Drug, and Cosmetic Act or regulation that is being violated. "We're seeing an expanded reinterpretation of what constitutes fair balance in these ads and promotional materials," she said.

Manufacturing and Inspection Changes

On the manufacturing front, the FDA has sought to incentivize testing and manufacturing of generic drugs in the United States. The agency announced a new pilot program to prioritize review of abbreviated new drug applications for applicants who conduct bioequivalence testing in the U.S. and whose active pharmaceutical ingredient supplier and finished dosage manufacturer are located in the U.S.

Karst questioned how beneficial the program would be since almost no ANDA sponsors meet these criteria. Mannion agreed, noting that generic manufacturers do not have deep pockets to make investments to bring manufacturing back to the U.S.

Among other actions last year, FDA expanded the use of unannounced inspections at foreign manufacturing facilities. The agency said it sought to end a double standard as American manufacturers do not receive notice of inspections while foreign firms often have weeks to prepare.

The agency also issued final guidance on conducting remote regulatory assessments of a company's compliance, such as by video livestream or teleconference. Mannion said she expects the agency will be using RRAs more frequently to increase the number of facilities it is communicating with. FDA conducts approximately 12,000 domestic inspections and 3,000 foreign inspections each year in more than 90 countries.